ATE420069T1 - Carboxamid derivate als muskarin rezeptor antagonisten - Google Patents

Carboxamid derivate als muskarin rezeptor antagonisten

Info

Publication number
ATE420069T1
ATE420069T1 AT06795581T AT06795581T ATE420069T1 AT E420069 T1 ATE420069 T1 AT E420069T1 AT 06795581 T AT06795581 T AT 06795581T AT 06795581 T AT06795581 T AT 06795581T AT E420069 T1 ATE420069 T1 AT E420069T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
carboxamide derivatives
muscarine receptor
muscarine
carboxamide
Prior art date
Application number
AT06795581T
Other languages
English (en)
Inventor
Paul Glossop
Simon MANTELL
Ross Strang
Christine Watson
Anthony Wood
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Application granted granted Critical
Publication of ATE420069T1 publication Critical patent/ATE420069T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
AT06795581T 2005-09-21 2006-09-01 Carboxamid derivate als muskarin rezeptor antagonisten ATE420069T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71946805P 2005-09-21 2005-09-21
US71946705P 2005-09-21 2005-09-21
US71947705P 2005-09-21 2005-09-21

Publications (1)

Publication Number Publication Date
ATE420069T1 true ATE420069T1 (de) 2009-01-15

Family

ID=37698323

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06795581T ATE420069T1 (de) 2005-09-21 2006-09-01 Carboxamid derivate als muskarin rezeptor antagonisten

Country Status (43)

Country Link
US (3) US7772223B2 (de)
EP (1) EP1928821B1 (de)
JP (1) JP4221447B1 (de)
KR (1) KR100976909B1 (de)
CN (1) CN101268046B (de)
AP (1) AP1983A (de)
AR (1) AR055171A1 (de)
AT (1) ATE420069T1 (de)
AU (1) AU2006293618B9 (de)
BR (1) BRPI0616111B8 (de)
CA (1) CA2623332C (de)
CR (2) CR9814A (de)
CU (1) CU20100115A7 (de)
CY (1) CY1108880T1 (de)
DE (1) DE602006004768D1 (de)
DK (1) DK1928821T3 (de)
DO (1) DOP2006000202A (de)
EA (1) EA013083B1 (de)
EC (1) ECSP088265A (de)
ES (1) ES2318794T3 (de)
GE (1) GEP20104880B (de)
GT (1) GT200600422A (de)
HK (1) HK1117163A1 (de)
HN (1) HN2006032615A (de)
HR (1) HRP20090127T3 (de)
IL (1) IL189453A (de)
MA (1) MA29839B1 (de)
ME (1) ME01106B (de)
MX (1) MX2008002805A (de)
MY (1) MY143581A (de)
NL (1) NL2000241C2 (de)
NO (1) NO340975B1 (de)
NZ (1) NZ566023A (de)
PE (1) PE20070460A1 (de)
PL (1) PL1928821T3 (de)
PT (1) PT1928821E (de)
RS (2) RS51680B (de)
SI (1) SI1928821T1 (de)
TN (1) TNSN08137A1 (de)
TW (1) TWI322143B (de)
UY (1) UY29798A1 (de)
WO (1) WO2007034325A1 (de)
ZA (1) ZA200801432B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
EP2066626B1 (de) * 2006-09-22 2010-03-17 Pfizer Limited Azetidinderivate als antagonisten des muskarinrezeptors
ATE512132T1 (de) * 2007-03-16 2011-06-15 Pfizer Ltd Hydrochloridsalz von 5-ä3-(3- hydroxyphenoxy)azetidin-1-ylü-5-methyl-2,2- diphenylhexanamid
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドPfizer Limited 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN103201244B (zh) * 2010-08-26 2015-06-17 阿尔比马尔公司 用于制备1-溴代-2-(环丙基甲氧基)-5-氟代-4-甲氧基苯的方法
CN103242214B (zh) * 2013-05-02 2016-04-06 陕西步长高新制药有限公司 一种吲哚衍生物及其制备方法
KR101538846B1 (ko) * 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
EP3596046A1 (de) 2017-03-15 2020-01-22 Mylan Laboratories Ltd. Neuartige polymorphe von (5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamid-hydrochlorid
PL3691620T3 (pl) 2017-10-05 2022-11-21 Fulcrum Therapeutics, Inc. Inhibitory kinazy p38 zmniejszają poziom ekspresji genu dux4 i dalszych genów do leczenia fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
EP3990091A4 (de) * 2019-06-25 2023-07-12 Mylan Laboratories Ltd. Verfahren und zwischenprodukte zur herstellung von hydrochloridsalz von 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamid
WO2021260441A1 (en) 2020-06-26 2021-12-30 Mylan Pharma Uk Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
WO2023049696A1 (en) * 2021-09-21 2023-03-30 Corteva Agriscience Llc Methylation of 2-chloro-6-fluorophenol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886574A (en) 1956-11-19 1959-05-12 Upjohn Co Quaternary ammonium salts of 2, 2-diphenyl-4, 4-dimethyl-4-pyrrolidino-butyramide
US4219559A (en) 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
GB8824262D0 (en) * 1988-10-17 1988-11-23 Pfizer Ltd Therapeutic agents
US5070087A (en) * 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6071950A (en) * 1996-12-02 2000-06-06 Kyorin Pharmaceutical Co., Ltd. N-substituted pyrrolidine derivatives and process for preparing the same
EP0848964B1 (de) * 1996-12-17 2007-07-25 Filtertek B.V. Rückschlagventil, insbesondere für die Medizintechnik
JPH11100366A (ja) * 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規n−置換環状アミン誘導体及びその製造法
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
CA2470956C (en) 2001-12-20 2011-08-02 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1375508A1 (de) 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-Substituierte Adenosin Derivate und ihre Verwendung als pharmazeutische Mittel
MXPA05002839A (es) 2002-09-17 2005-05-27 Actelion Pharmaceuticals Ltd Derivados de 1-piridin-4-il-urea.

Also Published As

Publication number Publication date
TNSN08137A1 (fr) 2009-07-14
AU2006293618A1 (en) 2007-03-29
DOP2006000202A (es) 2007-04-15
EP1928821A1 (de) 2008-06-11
ME01106B (me) 2013-03-20
BRPI0616111B8 (pt) 2021-05-25
ECSP088265A (es) 2008-04-28
EP1928821B1 (de) 2009-01-07
CN101268046A (zh) 2008-09-17
CR20130209A (es) 2013-09-19
GEP20104880B (en) 2010-01-11
EA013083B1 (ru) 2010-02-26
MX2008002805A (es) 2008-04-07
NO340975B1 (no) 2017-07-31
UY29798A1 (es) 2007-04-30
US20100029720A1 (en) 2010-02-04
EA200800540A1 (ru) 2008-08-29
US7772223B2 (en) 2010-08-10
TW200745024A (en) 2007-12-16
CR9814A (es) 2008-04-16
KR100976909B1 (ko) 2010-08-18
AP1983A (en) 2009-03-24
AR055171A1 (es) 2007-08-08
PL1928821T3 (pl) 2009-06-30
CY1108880T1 (el) 2014-07-02
IL189453A0 (en) 2008-08-07
US8268881B2 (en) 2012-09-18
HRP20090127T3 (en) 2009-06-30
CU23910B1 (de) 2013-06-29
PE20070460A1 (es) 2007-05-14
JP2009508933A (ja) 2009-03-05
DE602006004768D1 (de) 2009-02-26
NO20081001L (no) 2008-03-25
ES2318794T3 (es) 2009-05-01
CU20100115A7 (es) 2011-10-14
AU2006293618B9 (en) 2009-10-29
CA2623332C (en) 2012-05-01
NZ566023A (en) 2010-02-26
BRPI0616111B1 (pt) 2019-10-08
SI1928821T1 (sl) 2009-04-30
US20070105831A1 (en) 2007-05-10
WO2007034325A1 (en) 2007-03-29
PT1928821E (pt) 2009-03-10
RS50855B (sr) 2010-08-31
TWI322143B (en) 2010-03-21
US20110251164A1 (en) 2011-10-13
RS51680B (en) 2011-10-31
DK1928821T3 (da) 2009-03-16
MY143581A (en) 2011-05-31
CN101268046B (zh) 2012-07-25
MA29839B1 (fr) 2008-10-03
JP4221447B1 (ja) 2009-02-12
CA2623332A1 (en) 2007-03-29
HK1117163A1 (en) 2009-01-09
HN2006032615A (es) 2010-10-04
AU2006293618B2 (en) 2009-10-08
US8486992B2 (en) 2013-07-16
IL189453A (en) 2014-06-30
NL2000241C2 (nl) 2009-01-05
NL2000241A1 (nl) 2007-03-22
GT200600422A (es) 2007-05-28
BRPI0616111A2 (pt) 2011-06-07
RS20080119A (en) 2009-05-06
KR20080037103A (ko) 2008-04-29
ZA200801432B (en) 2009-07-29

Similar Documents

Publication Publication Date Title
ATE420069T1 (de) Carboxamid derivate als muskarin rezeptor antagonisten
ATE394391T1 (de) Indolderivate als histaminrezeptorantagonisten
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE420088T1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DK1951660T3 (da) Histamin-3-receptorantagonister
DK1677795T3 (da) Muskarine acetylcholin-receptor-antagonister
ATE413874T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
ATE523195T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
ATE540942T1 (de) Imidazolderivate als ccr2-rezeptor-antagonisten
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
ATE537151T1 (de) Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten
ATE485270T1 (de) 2-phenylindole als antagonisten des prostaglandin-d2-rezeptors
ATE535523T1 (de) Benzimidazolcarbonsäureamid-verbindungen als 5- ht4 rezeptor-agonisten
ATE462688T1 (de) Diarylsulfone als 5-ht2a-antagonisten
DE602006003666D1 (de) Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1928821

Country of ref document: EP